BridgeBio gets funding for drug launch; United buys into cell therapy

Otsuka kidney drugVertex CRISPR sickle cell drugPositive

AI Analysis

Summary

BridgeBio secured funding for drug launch while United Healthcare invested in cell therapy. Otsuka's kidney drug met its confirmatory trial endpoint and Vertex's CRISPR sickle cell therapy received expanded regulatory approval.

Clinical Trial Data

Primary Endpoint

Met

Importance:6/10

Sentiment:

0.70

fundingcell therapyCRISPRsickle cellregulatory approvalclinical trial

Related Companies

$BBOT $OTSKF $VRTX

Read the original article

Published by BioPharma Dive on July 1, 2026 3:29 PM

Read Original